IL‑17F promotes osteoblastic osteogenesis via the MAPK/ERK1/2 signaling pathway

Zhang,Na; Cui,Min; Liu,Xudong; Yu,Lingzhi; Zhao,Xu; Cao,Luning; Ji,Yuanyuan

doi:10.3892/etm.2021.10486

IL‑17F promotes osteoblastic osteogenesis via the MAPK/ERK1/2 signaling pathway

Authors:
- Na Zhang
- Min Cui
- Xudong Liu
- Lingzhi Yu
- Xu Zhao
- Luning Cao
- Yuanyuan Ji
View Affiliations

Affiliations: Department of Pain Medicine, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250013, P.R. China, Department of Pain Medicine, Shandong University Qilu Hospital, Jinan, Shandong 250012, P.R. China, Department of Anesthesiology, Shandong Provincial Hospital, Jinan, Shandong 250021, P.R. China, Department of Pain Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong 272001, P.R. China, Department of Anesthesiology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: July 23, 2021 https://doi.org/10.3892/etm.2021.10486
Article Number: 1052
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteoimmunology is a field that focuses on the interactions between the skeletal and immune systems, and has become a focus of research over the years. The role of interleukin (IL)‑17F, a proinflammatory cytokine, in bone regeneration and its signal transduction are not completely understood. The aim of the present study was to evaluate the function of IL‑17F and the possible mechanisms underlying IL‑17F in osteoblasts in vitro. Osteoblasts derived from newborn rats were treated with various concentrations of IL‑17F. The pro‑osteogenic effects of IL‑17F were assessed at the cellular and molecular level. The results demonstrated that IL‑17F promoted osteoblast proliferation, differentiation and mineralization. Reverse transcription‑quantitative PCR and western blotting indicated that IL‑17F treatment upregulated osteogenesis‑related factors, including bone morphogenetic protein‑2, Runt‑related transcription factor‑2 (Runx2) and Osterix, and downregulated Noggin compared with the control group. Subsequently, whether the IL‑17F receptors, IL‑17 receptor (IL‑17R) A and IL‑17RC, served a role in the effects of IL‑17F on osteoblasts was investigated. The mRNA expression levels of IL‑17RA and IL‑17RC were upregulated in IL‑17F‑treated osteoblasts compared with control osteoblasts. Furthermore, U0126, a MAPK/ERK1/2 inhibitor, was utilized to investigate the mechanisms underlying IL‑17F. The results indicated that compared with the control group, IL‑17F increased the protein expression of phosphorylated‑ERK1/2, Runx2 and Osterix, whereas U0126 reversed IL‑17F‑mediated effects. Collectively, the results of the present study suggested that IL‑17F promoted osteoblastic osteogenesis via the MAPK/ERK1/2‑mediated signaling pathway. IL‑17F promoted osteogenesis, including proliferation, differentiation and mineralization activity, indicating that IL‑17F may serve as a potential therapeutic target for osteoblast‑mediated bone loss disease.

View Figures

View References

1	Weitzmann MN and Pacifici R: Estrogen deficiency and bone loss: An inflammatory tale. J Clin Invest. 116:1186–1194. 2006.PubMed/NCBI View Article : Google Scholar
2	Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM and Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 6:1123–1132. 2005.PubMed/NCBI View Article : Google Scholar
3	Chyuan IT and Chen JY: Role of interleukin-(IL-) 17 in the pathogenesis and targeted therapies in spondyloarthropathies. Mediators Inflamm. 2018(2403935)2018.PubMed/NCBI View Article : Google Scholar
4	Wu S, Meng Z and Zhang Y: Correlation between rheumatoid arthritis and immunological changes in a rheumatoid arthritis rat model. J Biol Regul Homeost Agents. 32:1461–1466. 2018.PubMed/NCBI
5	Koo BS, Jo S, Kwon E, Shin JH, Hur JW and Kim TH: Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis. Korean J Intern Med. 35:465–473. 2020.PubMed/NCBI View Article : Google Scholar
6	Kim HJ, Seo SJ, Kim JY, Kim JY, Kim YG and Lee Y: IL-17 promotes osteoblast differentiation, bone regeneration, and remodeling in mice. Biochem Biophys Res Commun. 524:1044–1050. 2020.PubMed/NCBI View Article : Google Scholar
7	Miossec P and Kolls JK: Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 11:763–776. 2012.PubMed/NCBI View Article : Google Scholar
8	Patel DD and Kuchroo VK: Th17 cell pathway in human immunity: Lessons from genetics and therapeutic interventions. Immunity. 43:1040–1051. 2015.PubMed/NCBI View Article : Google Scholar
9	Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y and Takayanaqi H: IL-17 produing γδ T cells enhance bone regeneration. Nat Commun. 7(10928)2016.PubMed/NCBI View Article : Google Scholar
10	Osta B, Lavocat F, Eljaafari A and Miossec P: Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol. 5(425)2014.PubMed/NCBI View Article : Google Scholar
11	Nam D, Mau E, Wang Y, Wright D, Silkstone D, Whetstone H, Whyne C and Alman B: T-Lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. PLoS One. 7(e40044)2012.PubMed/NCBI View Article : Google Scholar
12	Wang Y, Kim J, Chan A, Whyne C and Nam D: A two phase regulation of bone regeneration: IL-17F mediates osteoblastogenesis via C/EBP-β in vitro. Bone. 116:47–57. 2018.PubMed/NCBI View Article : Google Scholar
13	Vachhani K, Pagotto A, Wang Y, Whyne C and Nam D: Design of experiments conﬁrms optimization of lithium administration parameters for enhanced fracture healing. J Biomech. 66:153–158. 2018.PubMed/NCBI View Article : Google Scholar
14	Yang W, Guo D, Harris MA, Cui Y, Gluhak-Heinrich J, Wu J, Chen XD, Skinner C, Nyman JS, Edwards JR, et al: Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. J Cell Sci. 126:4085–4098. 2013.PubMed/NCBI View Article : Google Scholar
15	Salazar VS, Gamer LW and Rosen V: BMP signaling in skeletal development, disease and repair. Nat Rev Endocrinol. 12:203–221. 2016.PubMed/NCBI View Article : Google Scholar
16	Cohen MM: Bone morphogenetic proteins with some comments on fibrodysplasia ossificans progressive and NOGGIN. Am J Med Genet. 109:87–92. 2002.PubMed/NCBI View Article : Google Scholar
17	Canalis E, Economides AN and Gazzerro E: Bone morphogenetic proteins, their antagonists, and the skeleton. Endocrine Rev. 24:218–235. 2003.PubMed/NCBI View Article : Google Scholar
18	Moffett SP, Dillon KA, Yerges LM, Goodrich LJ, Nestlerode C, Bunker CH, Wheeler VW, Patrick AL and Zmuda JM: Identification and association analysis of single nucleotide polymorphisms in the human noggin (NOG) gene and osteoporosis phenotypes. Bone. 44:999–1002. 2009.PubMed/NCBI View Article : Google Scholar
19	Komori T: Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 99:1233–1239. 2006.PubMed/NCBI View Article : Google Scholar
20	Amatya N, Garg AV and Gaffen SL: IL-17 signaling: The Yin and the Yang. Trends Immunol. 38:310–322. 2017.PubMed/NCBI View Article : Google Scholar
21	Ely LK, Fischer S and Garcia KC: Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol. 10:1245–1251. 2009.PubMed/NCBI View Article : Google Scholar
22	Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, Tocker J and Peschon J: Cutting edge: Interleukin 17 signals through a heteromeric receptor complex. J Immunol. 177:36–39. 2006.PubMed/NCBI View Article : Google Scholar
23	Gu C, Wu L and Li X: IL-17 family: Cytokines, receptors and signaling. Cytokine. 64:477–485. 2013.PubMed/NCBI View Article : Google Scholar
24	Schwandner R, Yamaguchi K and Cao Z: Requirement of tumor necrosis factor receptor-associated factor (TRAF) 6 in interleukin 17 signal transduction. J Exp Med. 191:1233–1240. 2000.PubMed/NCBI View Article : Google Scholar
25	Nguyen TT, Lian S, Ung TT, Xia Y, Han JY and Jung YD: Lithocholic acid stimulates IL-8 expression in human colorectal cancer cells via activation of Erk1/2 MAPK and Suppression of STAT3 Activity. J Cell Biochem. 118:2958–2967. 2017.PubMed/NCBI View Article : Google Scholar
26	Chen T, Huang H, Zhou Y, Geng L, Shen T, Yin S, Zhou L and Zheng S: HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways. J Exp Clin Cancer Res. 37(193)2018.PubMed/NCBI View Article : Google Scholar
27	Chen Q, Xia T and Ye ZW: New SD Rat osteoblasts by modified explant culture in vitro and identification. Acta Universitatis Medicinalis Anhui. 47:1124–1127. 2006.
28	Sun L and Hou JM: Primary culture and identification of rats cranial cover osteocytes. Med Innovation China. 8:17–19. 2011.
29	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
30	Orimo H: The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch. 77:4–12. 2010.PubMed/NCBI View Article : Google Scholar
31	Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE and Hromas R: Cutting edge: IL-17F, a novel cytokine selectively express in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol. 167:4137–4140. 2001.PubMed/NCBI View Article : Google Scholar
32	Kimura A and Kishimoto T: IL-6: Regulator of Treg/Th17 balance. Eur J Immunol. 40:1830–1835. 2010.PubMed/NCBI View Article : Google Scholar
33	Paradowska-Gorycka A, Sowinska A, Stypinska B, Grobelna MK, Walczyk M, Olesinska M, Piotrowski P and Jagodzinski PP: Impact of the IL-17F, IL-23 and IL-23R on susceptibility and phenotype of systemic lupus erythematosus. Autoimmunity. 49:373–382. 2016.PubMed/NCBI View Article : Google Scholar
34	Soderstrom C, Berstein G, Zhang W, Valdez H, Fitz L, Kuhn M and Fraser S: Ultra-sensitive measurement of IL-17A and IL-17F in psoriasis patient serum and skin. AAPS J. 19:1218–1222. 2017.PubMed/NCBI View Article : Google Scholar
35	Hatta M, Surachmanto EE, Islam AA and Wahid S: Expression of mRNA IL-17F and sIL-17F in atopic asthma patients. BMC Res Notes. 10(202)2017.PubMed/NCBI View Article : Google Scholar
36	Gomes da Silva IIF, Angelo HD, Rushansky E, Mariano MH, Diniz Maia MM and Eleuterio de Souza PRE: Interleukin (IL)-23 Receptor, IL-17A and IL-17F gene polymorphisms in brazilian patients with rheumatoid arthritis. Arch Immunol Ther Exp (Warsz). 65:537–543. 2017.PubMed/NCBI View Article : Google Scholar
37	Wang H, Zhang Y, Liu Z, Zhang Y, Zhao H and Du S: The IL-17A G-197A and IL-17F 7488T/C polymorphisms are associated with increased risk of cancer in Asians: A meta-analysis. Drug Des Devel Ther. 9:5159–5168. 2015.PubMed/NCBI View Article : Google Scholar
38	Erkolİnal E, Görükmez O, Eroğlu S, Özemri SŞ, Solak Ö, Görükmez Ö and Yakut T: Associations between polymorphisms of IL-17F and IL-17A genes with disease activity and clinical outcome of Ankylosing Spondylitis. Acta Reumatol Port. 41:232–239. 2016.PubMed/NCBI
39	Luu HH, Song WX, Luo X, Manning D, Lou J, Deng ZL, Sharff KA, Montag AG, Haydon RC and He TC: Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res. 2:665–677. 2007.PubMed/NCBI View Article : Google Scholar
40	Taşli PN, Aydin S, Yalvaç ME and Sahin F: Bmp 2 and bmp 7 induce odonto- and osteogenesis of human tooth germ stem cells. Appl Biochem Biotechnol. 172:3016–3025. 2014.PubMed/NCBI View Article : Google Scholar
41	Jimi E, Hirata S, Shin M, Yamazaki M and Fukushima H: Molecular mechanisms of BMP-induced bone formation: Cross-talk between BMP and NF-κB signaling pathways in osteoblastogenesis. Jpn Dent Sci Rev. 46:33–42. 2010.
42	Moon SH, Kim I and Kim SH: Mollugin enhances the osteogenic action of BMP-2 via the p38-Smad signaling pathway. Arch Pharm Res. 40:1328–1335. 2017.PubMed/NCBI View Article : Google Scholar
43	Kim EC, Yoon SJ, Noh K and Lee DW: Dual effect of curcumin/BMP-2 loaded in HA/PLL hydrogels on osteogenesis in vitro and in vivo. J Nanosci Nanotechnol. 17:143–152. 2017.PubMed/NCBI View Article : Google Scholar
44	Sun WL, Wang N and Xu Y: Impact of miR-302b on calcium-phosphorus metabolism and vascular calcification of rats with chronic renal failure by regulating BMP-2/Runx2/Osterix signaling pathway. Arch Med Res. 49:164–171. 2018.PubMed/NCBI View Article : Google Scholar
45	Yu X, Kawakami H, Tahara N, Olmer M, Hayashi S, Akiyama R, Bagchi A, Lotz M and Kawakami Y: Expression of Noggin and Gremlin1 and its implications in fine tuning BMP activities in mouse cartilage tissues. J Orthop Res. 35:1671–1682. 2017.PubMed/NCBI View Article : Google Scholar
46	AlShaibi HF, Ahmed F, Buckle C, Fowles ACM, Awlia J, Cecchini MG and Eaton C: The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells. Biotechnol Appl Biochem. 65:407–418. 2018.PubMed/NCBI View Article : Google Scholar
47	Yunan MA, Ying Y, Huanhuan S, Zhaozeng S, Lin Z and Yunzhi FA: Effect of Noggin silencing on the BMP and Wnt signaling pathways. Acta Laboratorium Animalis Scientia Sinica. 24:475–480. 2016.